Bone Biologics Corp

Insider Trading Arrangements

During the three months ended March 31, 2025, no director or officer of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Annual Meeting Date Change

As disclosed on our Current Report on Form 8-K filed with the SEC on April 21, 2025 (the “Form 8-K”), our Board of Directors determined on March 26, 2025 that the 2025 Annual Meeting will be held on May 30, 2025. The 2025 Annual Meeting date, the record date for the 2025 Annual Meeting and detailed information regarding the proposals to be presented at the 2025 Annual Meeting are set forth in our Definitive Proxy Statement on Schedule 14A filed with the SEC on April 23, 2025. Because the 2025 Annual Meeting will take place more than 30 days before the anniversary of our last annual meeting of stockholders, the due dates for the submission of any qualified shareholder proposal or qualified shareholder nominations under applicable SEC rules and our Amended and Restated Bylaws, as amended, listed in our Definitive Proxy Statement on Schedule 14A for our last annual meeting of stockholders, filed with the SEC on August 8, 2024, became no longer applicable. Such nominations or proposals, including any notice on Schedule 14N, were due to be received by the Company no later than Friday April, 11, 2025, which was ten calendar days following the disclosure of the 2025 Annual Meeting date on the Form 8-K.